Episode 1, Part 3 of PharmTech AI Pulse Check covers why INTerpath-001's AI isn't ChatGPT and names pharma manufacturing's biggest AI governance gaps.
|Webcasts|October 22, 2020
Particles, Powders and Pills – Optimized Raman across the Formulation Spectrum
Author(s)Renishaw
***Live:Friday, November 13, 2020 at 11am EST| 8am PST| 4pm GMT| 5pm CET *** From contaminants in injectables to the fate of APIs in nasal sprays, Raman reveals the identity and distribution of materials in complex formulations. In this webinar we describe the best approaches to characterizing common pharmaceutical samples; from morphologically targeted analysis of filtered particles to full three-dimensional chemical imaging of whole tablets.*** On demand available after final airing until Nov. 13, 2021.***
Register free:
Event Overview: This webcast will present methodologies to characterize a range of pharmaceutical materials from contaminant particles through to powders and pressed tablets. Each method requires an approach to ensure nothing is missed but analysis is rapid and complete. From selective pinpoint analysis based on particle morphology, to complete chemical images, the discussion will demonstrate how to optimize Raman data collection and analysis for the sample of interest.
Four cases will be covered
- Microparticles on a filter
- Deposits from nasal sprays
- Mixed powders
- Pressed tablets
Key Learning Objectives:
- How to speed analysis of large complex samples without data loss
- How to best analyze filtered particles
- The importance of magnification and focus to the analytical result
- Obtaining quantitative and qualitative data from images
- Understand the role of Raman spectroscopy in characterizing pharmaceutical products from dispersed particles through to whole tablets
Speakers: Tim Smith, Head of Applications, Renishaw Spectroscopy
Sarah Shidler, Ph.D, Applications Scientist,, Reinshaw Spectroscopy
Time and Date: Friday, November 13, 2020 at 11am EST| 8am PST| 4pm GMT| 5pm CET
On demand available after final airing until Nov. 13, 2021
Sponsor: Renishaw
Register free:
Related to this article
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.